New Delhi, India -- (SBWire) -- 01/04/2018 --Hereditary Angioedema (HAE) is an autosomal dominant disease which is caused by a deficiency in functional C1 inhibitor. It is a rare hereditary disease which is characterized by painful, unpredictable, recurrent attacks of inflammation and swelling affecting the hands, feet, face, abdomen, urogenital tract, and the larynx. This genetic disease is caused by the production of either inadequate or nonfunctioning C1-Inhibitor protein. The C1-Inhibitor helps in the regulation of the complex biochemical interactions of blood-based systems which are involved in disease-fighting, inflammatory responses, and coagulation.

According to the latest report of DelveInsight, "Hereditary Angioedema (HAE) – Market Insight, Epidemiology & Market Forecast, 2025", The total number of prevalent population of HAE was estimated to be around 18 thousand for 7MM in 2016. Among 7MM US accounts for the highest number of prevalent cases of HAE followed by EU5 and Japan. DelveInsight estimates that the prevalent population of HAE will significantly increase during the period of 2015-2025 in 7MM. Among EU5 German has accounted for the highest number of HAE prevalent cases and Italy for the lowest in 2015. Hereditary Angioedema Type I is a more frequent form of Hereditary Angioedema as compared to Hereditary Angioedema Type II and Hereditary Angioedema Type III in 7MM.

Market size of Hereditary Angioedema was estimated to be USD 1.2 Billion in 2016 for 7MM. Currently, the HAE market is dominated by drugs such as Berinert (CSL Behring GmbH), Cinryze (Shire), Ruconest (Pharming Technologies), Kalbitor (Shire), Firazyr (Shire) and Haegarda (CSL Behring) for the treatment of HAE. Although HAE therapeutic options have made a significant improvement but they still have limitations due to cost, side effects, and accessibility. Some upcoming therapies for the treatment of HAE are Haegarda (CSL Behring in June 2017), SHP643 (Shire in 2018), rhC1INH (Ruconest) & Ecallantide (Pharming & Shire respectively in 2021) & BCX7353 (Biocryst in 2022). According to DelveInsight, HAE market is expected to see a significant growth during the period of 2015-2025 due to the expected launch of the new therapies. The market is estimated to grow at a CAGR of 9.4% from 2015-2025.

The latest report has covered a detailed description of Disease Diagnostics, Diagnosis Algorithm, and Treatment. Competitive analysis providing complete Pipeline drugs profiling with each and every phase of development with clinical trials data. Global market size of HAE is provided for 2016 and 2025 to better understand the areas of improvement and growth opportunities in the market. Complete Epidemiology and patient population and prevalence details are provided covering the 7MM to better understand the major market scenario. Complete details of currently marketed drugs are provided to understand the key market players and their market performance. Information about all the possible market drivers and barriers is also provided to better understand the market and plan the strategies accordingly.

Reasons to buy:
- The report will help in developing business strategies by understanding trends shaping and driving the HAE market.
- To understand the future market competition in the HAE market and Insight reviews of the key market drivers and barriers.
- Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
- In-depth understanding of the pipeline development and recent happenings will provide a competitive edge over competitors.

Companies Covered:
- CSL Behring GmbH
- Shire
- Pharming Technologies
- Biocryst
And many others……………..

Table of Contents:
Report Introduction
Hereditary Angioedema Market Overview at a Glance: Global (2015-2025)
Total Market Share Distribution of Hereditary Angioedema for 7 MM in 2016
Total Market Share Distribution of Hereditary Angioedema for 7 MM in 2025
Hereditary Angioedema (HAE)
Overview
Types of Hereditary Angioedema (HAE)
Symptoms
Pathophysiology
Diagnosis
Diagnostic Algorithm
Treatment
Prophylaxis Algorithm
Epidemiology and Patient Population
Key Findings
Total number of Prevalent cases - 7MM Countries - (2016 & 2025)
Total number of Prevalent cases - Region wise - (2016 & 2025)
Distribution of Prevalent cases - 7MM Countries - (2016)
United States
Prevalent Cases of Hereditary Angioedema in United States
Distribution of Hereditary Angioedema - By Types
Prevalent Cases of Hereditary Angioedema - By Type
Germany
Prevalent Cases of Hereditary Angioedema in Germany
Distribution of Hereditary Angioedema - By Types
Prevalent Cases of Hereditary Angioedema - By Type
France
Prevalent Cases of Hereditary Angioedema in France
Distribution of Hereditary Angioedema - By Types
Prevalent Cases of Hereditary Angioedema - By Type
United Kingdom
Prevalent Cases of Hereditary Angioedema in United Kingdom
Distribution of Hereditary Angioedema - By Types
Prevalent Cases of Hereditary Angioedema - By Type
Spain
Prevalent Cases of Hereditary Angioedema in Spain
Distribution of Hereditary Angioedema - By Types
Prevalent Cases of Hereditary Angioedema - By Type
Italy
Prevalent Cases of Hereditary Angioedema in Italy
Distribution of Hereditary Angioedema by Types
Prevalent Cases of Hereditary Angioedema in by type - Italy
Market Forecast-2025
Japan
Prevalent Cases of Hereditary Angioedema in Japan
Distribution of Hereditary Angioedema by Types
Prevalent Cases of Hereditary Angioedema in by type - Japan
Emerging Therapies
SHP643
Product Profile
Clinical Development
Clinical Pipeline Activity
Ongoing Trials Information
Clinical Trial by Phase
Phase II
BCX7353
Product Profile
Clinical Development
Clinical Pipeline Activity
Ongoing Trials Information
Clinical Trial by Phase
Ruconest
Product Profile
Clinical Development
Clinical Pipeline Activity
Ongoing Trials Information
Clinical Trial by Phase
Kalbitor
Product Profile
Clinical Pipeline Activity
Ongoing Trials Information
Clinical Trial by Phase
Marketed Drugs for Hereditary Angioedema
Berinert: CSL Behring GmbH
Drug Description
Regulatory Milestones
Advantages & Disadvantages
Safety and Efficacy of Berinert
Product Profile
Cinryze: Shire
Drug Description
Regulatory Milestones
Advantages & Disadvantages
Safety and Efficacy of Cinryze
Product Profile
Ruconest: Pharming Technologies
Drug Description
Regulatory Milestones
Advantages & Disadvantages
Market Forecast-2025
Safety and Efficacy of Ruconest
Product Profile
Kalbitor: Shire
Drug Description
Regulatory Milestones
Advantages & Disadvantages
Safety and Efficacy of Kalbitor
Product Profile
Firazyr: Shire
Drug Description
Regulatory Milestones
Advantages & Disadvantages
Safety and Efficacy of Firazyr
Product Profile
Haegarda: CSL Behring
Drug Description
Regulatory Milestones
Advantages & Disadvantages
Safety and Efficacy of Firazyr
Product Profile
Hereditary Angioedema Market Overview: 7MM
Overview on Total Hereditary Angioedema Market (2016 & 2025)
7MM Hereditary Angioedema Market size (2016)
7MM Hereditary Angioedema Market size (2025)
Global Hereditary Angioedema: Market Analysis
United States Market Size
Europe Market Size
Germany Market Size
France Market Size
United Kingdom Market Size
Spain Market Size
Italy Market Size
Japan Market Size
Market Drivers
Market Barriers
Report Methodology
Consulting Services
Disclaimer

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. We support companies by providing end to end comprehensive solutions to improve their performance and in making a long-lasting decision for their businesses

We advise leading decision makers on their critical issues and opportunities; Research & Development, Strategy Making, Commercial, Operations, Competitive Intelligence, Competitive Landscaping and Mergers & Acquisition across all the Pharma and Biotech industries and geographies. We serve our clients by delivering practical and enduring results and equipping our clients to grow and lead.